Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

7 Dec 2025

Black patients with AML experience earlier onset and poorer outcomes

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period and supported by the National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health.

7 Dec 2025

A new generation of AML treatments brings hope for better survival

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates.

1 Dec 2025

New medication offers potential treatment for patients with deadliest form of blood cancer

Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for patients with the deadliest form of blood cancer.

25 Nov 2025

Young donor age proves critical for survival after stem cell transplantation

The selection of suitable donors is crucial for the long-term recovery of patients after an allogeneic hematopoietic stem cell transplantation (allo-HSCT).

21 Nov 2025

St. Jude scientists identify new therapeutic target for high-risk pediatric leukemia

Acute myeloid leukemia driven by tandem duplications within the UBTF gene (UBTF-TD AML) is a high-risk pediatric cancer in urgent need of novel therapeutic options.

3 Nov 2025

Dysfunction in chromosome-stabilizing protein identified as a cause of deadly illnesses

New research from the University of Wisconsin–Madison reveals that dysfunction in a protein essential to maintaining stability in our chromosomes may be responsible for serious - and sometimes deadly - diseases.

31 Oct 2025

Research shows the potential of structural nanomedicine in cancer treatment

In a promising advance for cancer treatment, Northwestern University scientists have re-engineered the molecular structure of a common chemotherapy drug, making it dramatically more soluble and effective and less toxic.

29 Oct 2025

Scientists discover why a powerful leukemia drug fails in most patients

Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients – and found a potential way to overcome that resistance.

17 Oct 2025

Age alone may not predict outcomes in acute myeloid leukemia

An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group reveals that age-based classifications in the treatment of acute myeloid leukemia (AML) may be outdated and overly simplistic.

14 Oct 2025

Targeting aggressive childhood leukemia with nanobody PROTACs

Scientists at the University of Duisburg-Essen are researching new therapies for aggressive forms of childhood leukemia.

13 Oct 2025

DKMS advances blood cancer research with groundbreaking ASAP study

The selection of patients for allo-HSCT and the best approach to bridging patients to transplantation is continuously discussed by experts.

6 Oct 2025

Newly discovered mechanism helps leukemia cells to evade the immune system

A research team at Lund University in Sweden has discovered a mechanism that helps acute myeloid leukemia cells to evade the body's immune system.

3 Oct 2025

New NIH-funded project aims to turn rare HIV cures into broadly applicable immunotherapy

Nearly 20 years ago, a man named Timothy Ray Brown who was living with HIV and cancer, underwent two courses of stem cell transplantation to treat his acute myeloid leukemia.

28 Aug 2025

Natural compound forskolin enhances chemotherapy effectiveness against aggressive leukemia

A natural compound could help fight aggressive leukaemia and amplify the effect of chemotherapy drugs.

26 Aug 2025

Research examines how cancer may invalidate forensic age-estimation tools

Patients with solid tumors, including breast and lung cancers, showed only slightly less accurate results. In contrast, individuals with blood cancers, particularly chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), sometimes had large errors, with ages overestimated by as much as 50 years.

22 Aug 2025

RUNX1C isoform identified as driver of chemoresistance in acute myeloid leukemia

One of the biggest challenges in cancer treatment is that certain cancers reappear after chemotherapy-and an aggressive type of blood cancer called acute myeloid leukemia (AML) is notorious for this.

17 Aug 2025

Many patients with high-risk myelodysplastic syndromes do not receive guideline-recommended treatment

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia.

6 Aug 2025

Immunotherapy shows promise in changing leukemia’s cellular environment

Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment - immunotherapy - may help change the environment where cancer cells live, possibly helping the immune system respond more effectively.

29 Jul 2025

Discovery of TAF1's role could revolutionize cancer treatment

A new study led by Stephen D. Nimer, M.D., director of Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, shows how a key molecule regulates the generation of new blood cells, a process called hematopoiesis that goes awry in cancer. The findings have the potential to lead to new therapeutic strategies targeting the molecule, a regulator of gene activity called TAF1.

26 Jul 2025